The Landscape of Biomarkers: From Traditional Measures to Multi-Omics Powerhouses
A biomarker is an indicator that can be quantified to show whether a biological process is pathogenic, normal, or responding to an intervention or exposure.
February 18, 2024
by Shruti Talshi
Research Progress in Signaling Pathway and Related Drugs of Target GDF15
GDF15 being a kind of endocrine hormone and a member of transforming growth factor β superfamily, acts as an autocrine regulatory molecule in macrophages, which was identified and found from the clone of activated macrophage cell line.
April 19, 2023
by Xiaonisha/PharmaSources
Biomarker may uncover uncontrolled asthma in adults, children: Research
Cytokine interleukin(IL)-26 could be used as biological marker for uncontrolled asthma in adults, children – could be future goal for new drugs against asthma
August 23, 2019
by expresspharma
Evolving World of Pharma: Addressing real-world challenges in personalized medicine
Earlier this year I wrote about a new model for healthcare – one of ‘personalized medicine’ – in which all patients receive exactly the right diagnoses and treatments, personalized to them as individuals.
June 25, 2019
by Sarah Harding
Definiens & Targos Innovation: AI-powered multiplex IHC biomarker analytic solutions for precision medicine
Definiens and Targos announced a collaboration for the integration of AI-powered data and multi-omics analytics of the tumor microenvironment with multiplexed immunohistochemistry (IHC) assay development in precision medicine global clinical trials.
June 24, 2019
by En-CPhI.cn
Mouth Rinse for HPV DNA May Be Biomarker in Head, Neck Cancer
Mouth Rinse for HPV DNA May Be Biomarker in Head, Neck Cancer.
June 11, 2019
by drugs
Roche launches HER2 biomarker test for breast and gastric cancer
Roche has launched a new assay that can detect the HER2 biomarker in breast and gastric cancer in the UK.
May 9, 2019
by pharmatimes
Breakdown of Blood-Brain Barrier May Drive Dementia
Breakdown of the blood-brain barrier (BBB) may be an early biomarker of cognitive dysfunction, independent of amyloid or tau marker status, according to a study published online Jan. 14 in Nature Medicine....
January 16, 2019
by drugs
Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01
Leap Therapeutics announced an investigator-initiated study led by David R. Wise, M.D., Ph.D. of the Perlmutter Cancer Center at NYU Langone Health to study DKN-01......
January 15, 2019
by americanpharmaceuticalreview
Biocartis, AstraZeneca aim faster lung cancer biomarker results
Many lung cancers are driven by mutations in the epidermal growth factor receptor (EGFR), which occur in 10-15% of NSCLC patients in the US and the EU, and 30-40% of NSCLC patients in Asia.
December 5, 2018
by biospectrumasia
FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).
November 28, 2018
by fda
Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?
Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations.
June 5, 2018
by fiercepharma